Centene's Turnaround Is Real — But OB3 Is the Bridge It Must Cross
Q2 EPS of $2.51 and a raised >$4.80 guide mask a quieter story: the Marketplace vindication, PDP's post-IRA stability, and a Medicaid portfolio bracing for OB3-driven attrition.
CNC · Earnings Call · 2026-07-28
The Quarter That Reframes the Year
Centene reported Q2 2026 adjusted EPS of $2.51, well above expectations, and lifted full-year guidance to >$4.80 from >$3.40. "We now expect full year 2026 adjusted diluted earnings per share of greater than $4.80, up from our prior outlook of greater than $3.40," said CEO Sarah London — but CFO Drew Asher was quick to flag the caveat: roughly $0.50 of the quarter's earnings came from settlements of 2025 items (about $180M from Marketplace risk adjustment reconciliation and $160M from Medicare PDP risk adjustment and quality settlements). “we had approximately $0.50 of earnings in the quarter that were linked to settlements of 2025 items in amounts that we wouldn't expect to recur in 2027” — Andrew Asher, Executive Vice President and Chief Financial Officer · 2026-07-28 — a reconciling item to keep in mind when modeling 2027.
This is a name in genuine motion toward margin restoration, and the market has noticed: the stock is up 74.3% over the last 90 trading days, a sharp break from its long drawdown.
Marketplace: The Vindication of an Expensive Bet
The biggest single change is in Marketplace. The company had prudently guided to a 3% pretax margin at the end of Q1, assuming elevated utilization among Silver-tier members and not fully embedding the corresponding risk adjustment offset. That posture was broken by two events in Q2: the June Wakely claims report — which corroborated the thesis that the company's higher-risk score Silver book would carry a meaningful risk adjustment receivable — and a favorable $180M development on the final 2025 CMS risk adjustment reconciliation. Result: Wakely data now underpins a revised full-year pretax margin of 4.5–5%, an improvement over both prior guidance and the initial February guide.
They saw and called a market-wide issue first. They leveraged more than a decade of experience and the breadth and depth of data that comes with operating in 29 markets to comprehensively diagnose the issue at hand.
This is a genuine inflection. On the Q1 call, management was still holding back, waiting for the first Wakely claims reports; now the same data confirms the market's acuity relative to Centene was better than guidance assumed. "We now expect to deliver a pretax margin between 4.5% and 5% for the Marketplace business for the full year," London said, signaling the segment is back on a normal margin trajectory after the 2025 industry detour. The contrast with a year ago is stark — then, on the Q3 2025 call, the company was flagging a September uptick in outpatient ED utilization and building prudence into 2026 pricing.
Medicaid: The OB3 Bridge and the Shrinking Expansion Pool
The counterweight to the good news is Medicaid membership attrition. The company now expects full-year membership down 8–9% versus the prior view of 6%, driven by state-level tightening and preparations for OB3 implementation. The expansion population is at the center: it was ~20% of Medicaid membership at the start of the year and will end around 18%. Drew Asher framed the tracking in the Q&A: “historically, about 20% of our membership, as of June 30, 19%, we expect within our guidance and our forecast down to 18%” — Andrew Asher, Executive Vice President and Chief Financial Officer · 2026-07-28.
Because the members rolling off skew toward the lower-utilizing end, management is watching the low utilizer cohort closely — and notes the drop is most pronounced precisely within the expansion population. Sarah London argues this is more manageable than the redeterminations unwind, partly because of the playbook around community engagement and workforce programs, and partly because of CMS guidance on mid-cycle and retro rate adjustments: “we do think it is a more manageable effort than what we went through with redeterminations” — Sarah London, Chief Executive Officer · 2026-07-28. The trade-off is explicit: the company is holding back 50 basis points of the improved rate forecast (now ~5% versus 4.5%) to absorb higher attrition and its associated acuity shift in the back half of the year. That is a deliberate and honest accounting of the risk.
On the prior call (April 2026), London had already positioned the company for this — when asked about the Silver cohort, she noted "we were positioned to retain and attract more Silver members who are now more acute in that overall post-APTC environment." That positioning is now paying off in the Marketplace result.
PDP and the Longer-Term Lever
PDP was also a positive surprise, with pretax margin guidance raised from 2% to >3%, helped by lower-than-expected specialty drug trends and prior-period true-ups. Post-IRA stability is now monetizing at roughly $25B of premium revenue. Meanwhile, the enterprise-optimization and AI agenda — from data products to dynamic context management — is framed as the multiyear SG&A lever, with management emphasizing a disciplined ROI bar rather than AI for its own sake.
The fundamentals confirm the operational turnaround at the margin level: operating margin rebounded to roughly 4% in early 2026, recovering from the -14% trough in Q3 2025 and a deeply negative 2025. Free cash flow swung strongly positive, and revenue continues to grow into an improving margin structure — about $50B in quarterly premium and service revenue, up ~7% year over year.
The story going forward is a balancing act: how long can Marketplace and PDP tailwinds offset the OB3 membership bleed in Medicaid? Management guides to margin progression through it — and the 90-day tape (+74%) suggests the market is beginning to buy that the trough is behind. The next genuine test is the 2027 bid season and how states set rates around the OB3 population shift.